['dravet syndrome']
['zx008 - 0.2 mg/kg/day', 'zx008 - 0.4 mg/kg/day', 'zx008 - 20 mg/day maximum dose', 'matching placebo']

        Key Inclusion Criteria:

          -  Subject must be male or non-pregnant, non-lactating female, age 2 to 18 years
             (inclusive)

          -  Subject must have documented medical history to support a clinical diagnosis of Dravet
             syndrome, where convulsive seizures are not completely controlled by current
             antiepileptic drugs.

          -  Subject must be receiving a therapeutically relevant and stable dose of CLB, VP, and
             STP for at least 4 weeks prior to screening and are expected to remain stable
             throughout the study (Cohort 2 only).

          -  Subject must be receiving a stable dose of CLB and VPA, administered twice daily, to
             be eligible for Dose Regimen 1 and 2 or subject must be receiving a stable dose of
             CLB, VPA, and STP, administered twice daily, to be eligible for Dose Regimen 3 (Cohort
             1 only).

        Key Exclusion Criteria:

          -  Subject has a known hypersensitivity to fenfluramine or any of the excipients in the
             study medication.

          -  Subject has pulmonary arterial hypertension.

          -  Subject has a current or past history of cardiovascular or cerebrovascular disease,
             such as cardiac valvulopathy, myocardial infarction or stroke.

          -  Subject has a current or recent history of anorexia nervosa, bulimia, or depression
             within the prior year that required medical treatment or psychological treatment for a
             duration greater than 1 month.

          -  Subject has a current or past history of glaucoma.

          -  Subject is receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine-oxidase inhibitors; any centrally-acting compound with clinically
             appreciable amount of serotonin agonist or antagonist properties, including serotonin
             re-uptake inhibition; triptans, atomoxetine, or other centrally-acting noradrenergic
             agonist; cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates.

          -  Subject is currently taking carbamazepine, oxcarbamazepine, eslicarbazepine,
             phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as
             maintenance therapy.

          -  Subject has a positive result on urine THC Panel or whole blood CBD at the Screening
             Visit.

          -  Subject has a clinically significant condition, or has had clinically relevant
             symptoms or a clinically significant illness in the 4 weeks prior to the Screening
             Visit, other than epilepsy, that would negatively impact study participation,
             collection of study data, or pose a risk to the subject.
      